AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX100.73+1.65 (+1.67%) ▲|SCHW92.04+0.40 (+0.44%) ▲|SO92.03+1.64 (+1.81%) ▲|SPG209.18+3.63 (+1.76%) ▲|T22.60+0.69 (+3.15%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN283.52-1.13 (-0.40%) ▼|UBER68.50+0.88 (+1.29%) ▲|UNH422.09+5.09 (+1.22%) ▲|UNP294.15+6.28 (+2.18%) ▲|UPS100.98+1.41 (+1.42%) ▲|USB59.68+0.63 (+1.06%) ▲|V410.99+3.14 (+0.77%) ▲|VZ44.82+1.26 (+2.88%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT118.77+0.97 (+0.82%) ▲|XOM176.60-1.49 (-0.84%) ▼|AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX100.73+1.65 (+1.67%) ▲|SCHW92.04+0.40 (+0.44%) ▲|SO92.03+1.64 (+1.81%) ▲|SPG209.18+3.63 (+1.76%) ▲|T22.60+0.69 (+3.15%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN283.52-1.13 (-0.40%) ▼|UBER68.50+0.88 (+1.29%) ▲|UNH422.09+5.09 (+1.22%) ▲|UNP294.15+6.28 (+2.18%) ▲|UPS100.98+1.41 (+1.42%) ▲|USB59.68+0.63 (+1.06%) ▲|V410.99+3.14 (+0.77%) ▲|VZ44.82+1.26 (+2.88%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT118.77+0.97 (+0.82%) ▲|XOM176.60-1.49 (-0.84%) ▼|
16.1 C
New York
Thursday, October 22, 2026

Tag: commission

newsFORsourcecompanycontentinformation1releasesmarket

SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

ICE Box Claims Evaluated: Personal Document Storage System for Organization & Secure Protection in Case of Emergencies

ICE Box organizes vital records, estate planning documents, and emergency files in one fireproof box with a 32GB USB stick and expert-developed checklist.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Glacier Breeze Portable AC: Features, Performance Claims & Consumer Feedback Evaluated in 2026

Madrid, Spain, June 13, 2026 (GLOBE NEWSWIRE) -- A 2026 company-aligned overview of how the Glacier Breeze Portable AC is presented across official product materials, including its Twin Frost Jet design, evaporative cooling technology, cooling cartridge system, and key considerations for consumers before purchasing.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCommission

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers